Treats hypertension. ANDA 216327, held by Sciegen Pharms. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 216327 (Diltiazem Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Apr 6, 2023, with 1 approved supplement and 0 published complete response letters.
Diltiazem Hydrochloride Extended-Release Tablet is a nondihydropyridine calcium channel blocker indicated for: treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. improving exercise tolerance in patients with chronic stable angina. 1.1 Hypertension Diltiazem Hydrochloride Extended-Release Tablets are indicated for the treatment of hypertension, to lower blood pressure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2023 | Original application | Approved | None posted |
| Diltiazem Hydrochloride120MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride300MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride360MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride420MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Apr 10, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 6, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters